Harvey Berger

Berger received his B.A. in Biology from Colgate University in 1972 and received his M.D. from Yale School of Medicine in 1977.{{Cite web|url=http://www4.colgate.edu/scene/sept2002/showcase.html|title=A showcase of alumni talent (The Colgate Scene, September 2002)|website=www4.colgate.edu|access-date=2017-09-25|archive-date=2018-10-01|archive-url=https://web.archive.org/web/20181001095235/http://www4.colgate.edu/scene/sept2002/showcase.html|url-status=dead}}{{Cite web|url=http://web.mit.edu/sloanhcc/bioinnovations/2011/bios.html|title=MIT Sloan BioInnovations 2011|website=web.mit.edu|language=en|access-date=2017-09-20}} He completed further medical and research training at the Massachusetts General Hospital and Yale-New Haven Hospital.

From 1986 until 1991, Berger held executive management positions at Centocor, Inc. including executive vice president and president of the Research and Development Division.{{Cite news|url=http://www.njbiz.com/article/20170216/NJBIZ01/170219863/medinol-appoints-executive-chairman-of-medinol-us|title=Medinol appoints executive chairman of Medinol US {{!}} NJBIZ|last=Bader|first=Emily|date=2017-02-16|work=NJBIZ|access-date=2017-09-23}} He led the development of Remicade® (infliximab), formerly known as Centara, a drug for the treatment of autoimmune diseases such as Crohn's disease, ulcerative colitis and rheumatoid arthritis, ReoPro® (abciximab), formerly known as CentoRx, a drug for the prevention of ischemic complications in patients with CAD undergoing percutaneous interventions,{{Cite web|url=https://www.thepharmaletter.com/article/us-approval-for-centocor-s-reopro|title=US Approval For Centocor's ReoPro – Pharmaceutical industry news|last=Letter|first=The Pharma|website=www.thepharmaletter.com|language=en|access-date=2017-09-25}}{{Cite web|url=https://www.scribd.com/document/2409904/Biotechnology-Report-Medicines-in-Development-2006|title=Biotechnology Report, Medicines in Development, 2006 {{!}} Interleukin 2 {{!}} Monoclonal Antibody|website=Scribd|language=en|access-date=2017-09-25}} and the cancer diagnostic test, CA125, to evaluate patients with ovarian cancer.{{Cite journal|url=http://www.cancernetwork.com/ovarian-cancer/centocor-ca-125-ii-new-version-ca-125-assay-now-available|title=Centocor CA 125 II, New Version of CA 125 Assay, Is Now Available {{!}} Cancer Network|website=www.cancernetwork.com|series=Oncology NEWS International Vol 4 No 5 |date=May 1995 |volume=4 |issue=5 |language=en|access-date=2018-03-20}}{{Cite journal|last1=Matsukura|first1=A.|last2=Nakazawa|first2=Y.|last3=Hama|first3=S.|date=November 1989|title=[A shortened method for the assay with Centocor radioimmunoassay kit]|journal=Radioisotopes|volume=38|issue=11|pages=469–472|issn=0033-8303|pmid=2595020|doi=10.3769/radioisotopes.38.11_469|doi-access=free}}

In 1991, Berger founded ARIAD Pharmaceuticals in Cambridge, Massachusetts.{{Cite news|url=https://www.bostonglobe.com/business/2016/07/15/ariad-moving-new-kendall-square-headquarters/UZ3B7lpItiwg6xa1SiXV6L/story.html|title=Ariad moving to new Kendall Square headquarters – The Boston Globe|work=BostonGlobe.com|access-date=2017-09-24}}{{Cite web|url=https://www.bizjournals.com/boston/news/2017/01/11/former-ariad-ceo-berger-says-takeda-deal-was.html|title=Former Ariad CEO Berger says Takeda deal was 'merely a matter of time'|website=www.bizjournals.com|access-date=2017-09-24}} He served as chairman and CEO from 1991 to 2015. In 1992, ARIAD raised $46 million, the largest single round of financing for a startup in the biotechnology industry at the time.{{Cite news|url=https://www.nytimes.com/1992/03/27/business/company-news-ariad-raises-46-million-in-placement.html|title=COMPANY NEWS; Ariad Raises $46 Million In Placement|last=Pollack|first=Rew|date=1992-03-27|work=The New York Times|access-date=2017-09-25|language=en-US|issn=0362-4331}} ARIAD's plan was to develop drugs that would interfere with communication signals within cells, rather than on the cell surface or in between cells. In 1994, ARIAD filed for an initial public offering and was listed on the NASDAQ market.{{Cite news|url=https://www.nytimes.com/1994/05/16/business/equity-issues-this-week.html|title=Equity Issues This Week|date=1994-05-16|work=The New York Times|access-date=2017-09-25|language=en-US|issn=0362-4331}}{{Cite news|url=http://www.nasdaq.com/article/ariad-pharmaceuticals-inc-aria-stock-higher-on-takeda-buyout-news-cm731041|title=Ariad Pharmaceuticals, Inc. (ARIA) Stock Higher on Takeda Buyout News|date=2017-01-09|work=NASDAQ.com|access-date=2017-09-25|language=en-us}}

In 2000, Berger focused ARIAD on oncology, based on recent discoveries in the human genome.{{Cite web|url=http://www.pmlive.com/pharma_thought_leadership/interview_harvey_berger_and_timothy_clackson,_ariad_509032|title=Interview: Harvey Berger and Timothy Clackson, Ariad|date=2013-10-14|website=www.pmlive.com|language=en|access-date=2017-09-20}} Under Berger's leadership, ARIAD grew to over 365 U.S. employees and established a European headquarters in Lausanne, Switzerland.{{Cite web|url=https://www.bizjournals.com/boston/blog/bioflash/2014/10/ariad-s-harvey-berger-says-he-s-absolutely-secure.html|title=Ariad's Harvey Berger says he's 'absolutely' secure in his role as CEO|website=www.bizjournals.com|access-date=2017-09-25}}{{Cite web|url=https://www.bizjournals.com/boston/blog/bioflash/2016/05/ariad-sells-european-operations-for-140m-upfront.html|title=Ariad sells European operations for $140M upfront plus royalties|website=www.bizjournals.com|access-date=2017-09-25}}

While Berger was CEO, ARIAD developed five new medicines including the blood-cancer drug Iclusig, Brigatinib, a lung cancer treatment and AP32788 (now known as TAK788), a new medicine for lung cancer with novel mutated genetic targets.{{Cite news|url=https://lungdiseasenews.com/2016/04/22/positive-preclinical-results-lung-cancer-drug-announced-annual-meeting-cancer-research/|title=Positive Preclinical Results for Lung Cancer Drug Announced at Annual Meeting of Cancer Research – Lung Disease News|date=2016-04-22|work=Lung Disease News|access-date=2017-09-24|language=en-US}}

Brigatinib is approved for use in the U.S.{{Cite journal|last=Research|first=Center for Drug Evaluation and|date=2020-05-26|title=FDA approves brigatinib for ALK-positive metastatic NSCLC|url=https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-brigatinib-alk-positive-metastatic-nsclc|journal=FDA|language=en}} and Europe,{{Cite news|date=2020-04-06|title=BRIEF-Takeda Says European Commission Approved Alunbrig As A First-Line Treatment For ALK+ NSCLC|language=en|work=Reuters|url=https://www.reuters.com/article/brief-takeda-says-european-commission-ap-idUSFWN2BU0PG|access-date=2020-06-26}}{{Cite web|last=McKee|first=Selina|date=2020-04-08|title=Expanded EU approval for Takeda's Alunbrig|url=http://www.pharmatimes.com/news/expanded_eu_approval_for_takedas_alunbrig_1337936|access-date=2020-06-26|website=PharmaTimes|language=en}} and TAK788 is continuing a global phase 3 trial.{{Cite web|last=|first=|date=25 May 2020|title=Takeda's Approval and Other News: The Good, Bad And Ugly of Biopharma|url=https://seekingalpha.com/article/4349874-takedas-approval-and-news-good-bad-and-ugly-of-biopharma|access-date=|website=}}

At the end of 2015, Berger retired from ARIAD and became an advisor to the board of directors.{{Cite web|url=http://investor.ariad.com/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=2041309|title=ARIAD Founder, Harvey J. Berger, M.D., to Retire as Chairman and Chief Executive Officer|website=ARIAD Pharmaceuticals, Inc.|language=en|access-date=2017-09-24}} In early 2017, ARIAD was acquired by Takeda Pharmaceuticals, Ltd. for $5.2 billion, becoming part of Takeda Oncology.{{Cite web|url=http://www.bizjournals.com/boston/news/2017/01/11/former-ariad-ceo-berger-says-takeda-deal-was.html|title=Former Ariad CEO Berger says Takeda deal was 'merely a matter of time'|website=www.bizjournals.com|access-date=2017-09-23}}

In February 2017, Medinol, Inc. announced that Berger would be serving as its executive chairman.{{Cite news|url=https://www.bostonglobe.com/business/talking-points/2017/02/21/berger-named-post-medinol/590Hk5e1fkvyEiqE2Uw6HN/story.html|title=Berger named to post at Medinol – The Boston Globe|work=BostonGlobe.com|access-date=2017-09-25}} On the global management team, his focuses at Medinol would include business management, global strategy, new business and technology initiatives, as well as improving operational efficiency as the company expands worldwide.{{Cite news|url=http://www.cardiovascularbusiness.com/topics/coronary-intervention-surgery/medinol-hires-harvey-berger-executive-chairman-its-us-operations|title=Medinol hires Harvey Berger as executive chairman of its US operations|work=Cardiovascular Business|access-date=2017-09-23}} Berger's role at Medinol was said to include working with their core business of interventional cardiovascular devices, along with its new businesses developing percutaneous aortic valves, sub-millimeter implantable sensors, and related products. He retired from Medinol at the end of 2018.{{Cite web|title=Harvey Berger {{!}} About|url=https://harveyberger.com/about-harvey-berger/|access-date=2020-06-26|website=Harvey Berger|language=en-US}} In 2019, Berger retired as chairman and chief executive officer emeritus of ARIAD.

Berger has served on the Board of Trustees at Concord Academy.{{Cite web|title=CA Magazine Fall 2018|url=https://issuu.com/concord_academy/docs/camagazine_fall2018|access-date=2020-06-26|website=Issuu|date=5 November 2018 |language=en}}

Berger has held senior academic and administrative roles at Emory University, Yale University and the University of Pennsylvania. He was also a member of the Dean's Council of Yale University School of Medicine. During his time at Emory, Berger led a program for developing cardiovascular single-photon emission computed tomographic (SPECT) imaging, supported by General Electric Medical Systems.{{Cite journal|last1=DePasquale|first1=E. E.|last2=Nody|first2=A. C.|last3=DePuey|first3=E. G.|last4=Garcia|first4=E. V.|last5=Pilcher|first5=G.|last6=Bredlau|first6=C.|last7=Roubin|first7=G.|last8=Gober|first8=A.|last9=Gruentzig|first9=A.|date=1988-02-01|title=Quantitative rotational thallium-201 tomography for identifying and localizing coronary artery disease.|url=http://circ.ahajournals.org/content/77/2/316|journal=Circulation|language=en|volume=77|issue=2|pages=316–327|doi=10.1161/01.CIR.77.2.316|issn=0009-7322|pmid=3257422|doi-access=free}} He and other colleagues at Emory collaborated on the development of new quantitative techniques for cardiac SPECT imaging.{{Cite journal|last1=Berger|first1=Harvey J.|last2=Eisner|first2=Robert|last3=DePuey|first3=E. Gordon|last4=Patterson|first4=Randolph|date=1984-11-01|title=New Vistas in Cardiovascular Nuclear Medicine|url=http://jnm.snmjournals.org/content/25/11/1254|journal=Journal of Nuclear Medicine|language=en|volume=25|issue=11|pages=1254–1258|issn=0161-5505|pmid=6333498}}

Berger has contributed to a wide range of medical journals including the New England Journal of Medicine and American Journal of Cardiology,{{Cite journal|last1=Ziegler|first1=Elizabeth J.|last2=Fisher|first2=Charles J.|last3=Sprung|first3=Charles L.|last4=Straube|first4=Richard C.|last5=Sadoff|first5=Jerald C.|last6=Foulke|first6=Garrett E.|last7=Wortel|first7=Cornelis H.|last8=Fink|first8=Mitchell P.|last9=Dellinger|first9=R. Phillip|title=Treatment of Gram-Negative Bacteremia and Septic Shock with HA-1A Human Monoclonal Antibody against Endotoxin|journal=New England Journal of Medicine|volume=324|issue=7|pages=429–436|doi=10.1056/nejm199102143240701|pmid=1988827|year=1991|doi-access=free}}{{Cite journal|last1=Johnstone|first1=David E.|last2=Sands|first2=Milton J.|last3=Berger|first3=Harvey J.|last4=Reduto|first4=Lawrence A.|last5=Lachman|first5=Anthony S.|last6=Wackers|first6=Frans J. Th|last7=Cohen|first7=Lawrence S.|last8=Gottschalk|first8=Alexander|last9=Zaret|first9=Barry L.|date=1980-06-01|title=Comparison of exercise radionuclide angiocardiography and thallium-201 myocardial perfusion imaging in coronary artery disease|url=http://www.ajconline.org/article/0002-9149(80)90467-1/abstract|journal=American Journal of Cardiology|language=English|volume=45|issue=6|pages=1113–1119|doi=10.1016/0002-9149(80)90467-1|issn=0002-9149|pmid=7377108}} and has been interviewed by Fox Business{{Cite web|url=https://video.foxbusiness.com/v/1057891706001/?#sp=show-clips|title=Ariad CEO on Developing New Drugs|date=2011-07-15|website=Fox Business|language=en-US|access-date=2017-11-10}}{{Cite web|url=https://video.foxbusiness.com/v/1268818084001/?#sp=show-clips|title=Ariad CEO on the Three Drugs in the Pipeline for Cancer Treatment|date=2011-11-10|website=Fox Business|language=en-US|access-date=2017-11-10}}{{Cite web|url=https://video.foxbusiness.com/v/1769395067001/?#sp=show-clips|title=Ariad Pharmaceuticals Working on Cancer 'Miracle Pill'|date=2012-08-03|website=Fox Business|language=en-US|access-date=2017-11-10}}{{Cite web|url=https://video.foxbusiness.com/v/1680540476001/?#sp=show-clips|title=Ariad Pharmaceuticals CEO on a New Leukemia Drug|date=2012-06-08|website=Fox Business|language=en-US|access-date=2017-11-10}} and CNBC.{{Cite news|url=https://www.cnbc.com/2012/06/04/cramer-interviews-ariad-pharma-ceo.html|title=Cramer Interviews Ariad Pharma CEO|last=Chang|first=Kirsten|date=2012-06-04|work=CNBC|access-date=2017-11-10}} He was also an established investigator of the American Heart Association.

In 2013, Berger was awarded the Ernst & Young Entrepreneur of the Year Award for the New England Region. The award recognizes success in innovation, financial performance, personal commitment to their business communities and other areas.{{Cite news|url=https://www.aol.com/article/finance/2013/06/28/ariad-chief-executive-officer-harvey-j-berger-md-r/20641976/|title=ARIAD Chief Executive Officer, Harvey J. Berger, M.D., Recognized as 2013 Ernst & Young Entrepreneur|author=AOL Staff|work=AOL.com|access-date=2017-09-21|language=en}} Also in 2013, Berger was awarded a Gold Stevie Award.{{Cite web|last=|first=|date=18 June 2013|title=ARIAD Honored With Gold Stevie Awards As Pharmaceutical Company Of The Year At 2013 American Business Awards|url=https://www.thestreet.com/story/11953959/1/ariad-honored-with-gold-stevie174-awards-as-pharmaceutical-company-of-the-year-at-2013-american-business-awardssm.html|url-status=live|archive-url=https://web.archive.org/web/20170926041124/https://www.thestreet.com/story/11953959/1/ariad-honored-with-gold-stevie174-awards-as-pharmaceutical-company-of-the-year-at-2013-american-business-awardssm.html|archive-date=26 September 2017|access-date=|website=The Street}}{{Cite web|title=Harvey J. Berger, M.D. '77 Appointed Executive Chairman, Medinol Inc.|url=https://medicine.yale.edu/ysm/news-article/15926/|access-date=2020-06-26|website=Yale School of Medicine|language=en}}

Berger resides in Palm Beach, Florida, with his wife Chrysanthi and their two daughters, Isabella Grace Berger and Nicole Elizabeth Berger, an actress.{{Cite news|url=http://www.palmbeachdailynews.com/lifestyles/society/palm-beach-year-old-gets-broadway-bash-and-visit-from-flo-rida/enaYRQwO0kedVgNDKeuSFP/|title=Palm Beach 13-year-old gets Broadway bash – and a visit from Flo Rida|work=palmbeachdailynews|access-date=2017-09-23|language=en}}{{Cite web|url=http://ymm.yale.edu/autumn2008/people/alumni/|title=Alumni > Autumn 2008 {{!}} Yale Medicine|website=ymm.yale.edu|access-date=2017-11-10}} Harvey and Chrysanthi Berger have supported the Palm Beach Day Academy, the American Cancer Society, and the Dana–Farber Cancer Institute.{{Cite news|url=http://www.palmbeachdailynews.com/lifestyles/jukebox-hero-gramm-brings-80s-life-for-american-cancer-society/s2ltR420PfHi9irPyevALO/|title='Jukebox Hero' Gramm brings '80s to life for American Cancer Society|work=palmbeachdailynews|access-date=2017-11-10|language=en}}{{Cite news|url=http://www.newyorksocialdiary.com/party-pictures/2017/mad-pmp-hss-and-pbda|title=MAD, PMP, HSS, and PBDA|date=2017-03-20|work=New York Social Diary|access-date=2017-11-10|language=en}}{{Cite web|last=Donnelly|first=Shannon|title=Palm Beach society: Katie Couric shares slices of life at Dana–Farber Cancer Institute donors dinner|url=https://www.heraldtribune.com/news/20190217/palm-beach-society-katie-couric-shares-slices-of-life-at-dana-farber-cancer-institute-donors-dinner|access-date=2020-06-26|website=Sarasota Herald-Tribune|language=en}} In February 2018, Berger was appointed to the Dana–Farber Cancer Institute Board of Trustees, the governing board of the organization.{{Cite web|url=http://www.dana-farber.org/newsroom/news-releases/2018/dana-farber-cancer-institute-appoints-six-new-members-to-board-of-trustees/|title=Dana–Farber Cancer Institute appoints six new members to Board of Trustees – Dana–Farber Cancer Institute {{!}} Boston, MA|website=www.dana-farber.org|language=en|access-date=2018-03-20}}

{{Reflist|2}}

{{DEFAULTSORT:Berger, Harvey}}

Category:1950 births

Category:Living people

Category:American health care chief executives

Category:Colgate University alumni

Category:Yale School of Medicine alumni